Literature DB >> 23483243

Evaluation by N-terminal prohormone of brain natriuretic peptide concentrations and ross scoring of the efficacy of digoxin in the treatment of heart failure secondary to congenital heart disease with left-to-right shunts.

Ozlem Elkiran1, Ayse Sandikkaya, Gulendam Kocak, Cemsit Karakurt, Cagatay Taskapan, Saim Yologlu.   

Abstract

This study aimed to evaluate the effectiveness of digoxin in children with heart failure secondary to left-to-right shunt lesions and normal left ventricular systolic function. The study registered 37 such patients (ages 10 days to 24 months, groups 1 and 2) and used 20 healthy children as a control group (group 3). Left ventricular systolic function, as assessed by conventional echocardiography, was normal in all the subjects. Congestive heart failure was diagnosed by clinical evaluation and modified Ross scoring. Plasma N-terminal prohormone of brain natriuretic peptide (NT-proBNP) concentrations and complete blood counts were assessed in all the children. Group 1 was treated with digoxin, enalapril, and furosemide and group 2 with enalapril and furosemide. Approximately 1 month after starting treatment, the patients were reevaluated by physical and echocardiographic examinations, modified Ross scoring, plasma NT-proBNP concentrations, and complete blood counts. The pre- and posttreatment Ross scores of group 1 (p = 0.377) and group 2 (p = 0.616) did not differ significantly. The NT-proBNP values in both groups decreased after treatment (p = 0.0001). The pre- and posttreatment NT-proBNP values did not differ significantly in group 1 (p = 0.094)) and group 2 (p = 0.372). The pretreatment NT-proBNP values in groups 1 and 2 (p = 0.0001) were significantly higher than in the control group (p = 0.003). A smaller difference was observed between posttreatment NT-proBNP values in group 1 and the control group (p = 0.045). We found no significant difference between the posttreatment NT-proBNP values of group 2 and those of the control group (p = 0.271). The study showed that both treatments currently used to treat heart failure secondary to congenital heart disease with left-to-right shunts and preserved left ventricular systolic function are effective and do not differ significantly. Thus, digoxin does not provide any extra benefit in the treatment of such patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23483243     DOI: 10.1007/s00246-013-0683-7

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  34 in total

Review 1.  The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision.

Authors:  Robert D Ross
Journal:  Pediatr Cardiol       Date:  2012-04-05       Impact factor: 1.655

Review 2.  Does digoxin still have a role in congestive heart failure?

Authors:  S S Kothari
Journal:  Indian J Pediatr       Date:  1997 Nov-Dec       Impact factor: 1.967

Review 3.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

Review 4.  Optimizing treatment for chronic congestive heart failure in children.

Authors:  R E Shaddy
Journal:  Crit Care Med       Date:  2001-10       Impact factor: 7.598

Review 5.  Novel therapies in childhood heart failure: today and tomorrow.

Authors:  Daniel J Penny; Giles Wesley Vick
Journal:  Heart Fail Clin       Date:  2010-10       Impact factor: 3.179

Review 6.  Clinical practice: heart failure in children. Part I: clinical evaluation, diagnostic testing, and initial medical management.

Authors:  Paul F Kantor; Luc L Mertens
Journal:  Eur J Pediatr       Date:  2009-08-26       Impact factor: 3.183

7.  Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants.

Authors:  V F Puddy; C Amirmansour; A F Williams; D R J Singer
Journal:  Clin Sci (Lond)       Date:  2002-07       Impact factor: 6.124

8.  N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases.

Authors:  A Nir; B Bar-Oz; Z Perles; R Brooks; A Korach; A J J T Rein
Journal:  Acta Paediatr       Date:  2004-05       Impact factor: 2.299

Review 9.  Diagnosis and management of heart failure. Canadian Cardiovascular Society.

Authors:  D E Johnstone; A Abdulla; J M Arnold; V Bernstein; M Bourassa; J Brophy; R Davies; M Gardner; R Hoeschen; L Mickleborough
Journal:  Can J Cardiol       Date:  1994 Jul-Aug       Impact factor: 5.223

10.  Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth.

Authors:  M Yoshibayashi; T Kamiya; Y Saito; K Nakao; K Nishioka; S Temma; H Itoh; G Shirakami; H Matsuo
Journal:  Eur J Endocrinol       Date:  1995-08       Impact factor: 6.664

View more
  2 in total

1.  Preterm birth and prescriptions for cardiovascular, antiseizure, antibiotics and antiasthmatic medication in children up to 10 years of age: a population-based data linkage cohort study across six European regions.

Authors:  Mads Damkjaer; Maria Loane; Stine Kjær Urhøj; Elisa Ballardini; Clara Cavero-Carbonell; Alessio Coi; Laura García-Villodre; Joanne Emma Given; Mika Gissler; Anna Heino; Susan Jordan; Amanda Neville; Anna Pierini; Joachim Tan; Ieuan Scanlon; Ester Garne; Joan K Morris
Journal:  BMJ Open       Date:  2022-10-17       Impact factor: 3.006

Review 2.  "Nihilism" of chronic heart failure therapy in children and why effective therapy is withheld.

Authors:  Dietmar Schranz; Norbert F Voelkel
Journal:  Eur J Pediatr       Date:  2016-02-19       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.